Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gynecologic 2Genitourinary 2Gastrointestinal 2Thoracic 1Head & Neck 1Endocrine 1Dermatologic 1CNS 1

Conditions

Melanoma 31Carcinoma, Renal Cell 19Carcinoma, Non-Small-Cell Lung 19Neoplasm Metastasis 11Carcinoma, Hepatocellular 9Brain Neoplasms 8Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Pancreatic Neoplasms 5Lung Neoplasms 5Clear-cell metastatic renal cell carcinoma 5Carcinoma, Transitional Cell 5Uveal Melanoma 4Skin Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Multiple Myeloma 4Mesothelioma 4Kidney Neoplasms 4Glioblastoma 4Carcinoma, Basal Cell 4Carcinoma 4Sarcoma 3Recurrence 3Myelodysplastic Syndromes 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Gliosarcoma 3Colorectal Neoplasms 3Breast Neoplasms 3

Interventions

pembrolizumab 2durvalumab 2Paclitaxel 2Nivolumab 2Ipilimumab 2Doxorubicin 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1talazoparib 1spartalizumab 1selinexor 1sarilumab 1pexidartinib 1pertuzumab 1pazopanib 1patritumab 1olaparib 1niraparib 1neratinib 1ganitumab 1dostarlimab 1cemiplimab 1balstilimab 1abemaciclib 1Trastuzumab 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hemangiosarcoma × Ipilimumab × 90 days × Clear all
NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
798 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Agenus Inc.

Phase 1 Active not recruiting
499 enrolled
GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡